Nuveen
BCRX icon

Nuveen’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nuveen’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.1M Buy
4,007,237
+187,974
+5% +$1.7M 0.01% 837
2026
Q1 		$36.4M Buy
3,819,263
+206,897
+6% +$1.61M 0.01% 799
2025
Q4 		$28.2M Sell
3,612,366
-5,516
-0.2% -$39.9K 0.01% 942
2025
Q3 		$27.5M Buy
3,617,882
+83,428
+2% +$695K 0.01% 950
2025
Q2 		$31.7M Buy
3,534,454
+2,110,808
+148% +$19.7M 0.01% 826
2025
Q1 		$17.2M Sell
1,423,646
-1,995,400
-58% -$16.1M 0.01% 1213
2024
Q4 		$25.7M Sell
3,419,046
-1,395,503
-29% -$10.6M 0.01% 1001
2024
Q3 		$36.6M Buy
4,814,549
+319,164
+7% +$2.43M 0.01% 818
2024
Q2 		$27.8M Buy
4,495,385
+1,875,524
+72% +$10.3M 0.01% 918
2024
Q1 		$13.3M Sell
2,619,861
-847,103
-24% -$4.76M ﹤0.01% 1426
2023
Q4 		$20.8M Buy
3,466,964
+893,624
+35% +$5.18M 0.01% 1136
2023
Q3 		$18.2M Buy
2,573,340
+1,577,857
+159% +$11.3M 0.01% 1095
2023
Q2 		$7.01M Buy
995,483
+199,184
+25% +$1.6M ﹤0.01% 1724
2023
Q1 		$6.64M Sell
796,299
-809,395
-50% -$7.79M ﹤0.01% 1732
2022
Q4 		$18.4M Sell
1,605,694
-297,127
-16% -$3.71M 0.01% 1097
2022
Q3 		$24M Sell
1,902,821
-23,013
-1% -$296K 0.01% 901
2022
Q2 		$20.4M Sell
1,925,834
-531,381
-22% -$5.48M 0.01% 1040
2022
Q1 		$38.8M Buy
2,457,215
+96,290
+4% +$1.54M 0.01% 757
2021
Q4 		$32.7M Sell
2,360,925
-68,761
-3% -$910K 0.01% 932
2021
Q3 		$34.9M Sell
2,429,686
-135,734
-5% -$2.14M 0.01% 892
2021
Q2 		$40.6M Buy
2,565,420
+61,065
+2% +$830K 0.01% 863
2021
Q1 		$25.5M Buy
2,504,355
+931,841
+59% +$9.61M 0.01% 1146
2020
Q4 		$11.7M Sell
1,572,514
-54,093
-3% -$279K ﹤0.01% 1600
2020
Q3 		$5.59M Sell
1,626,607
-60,201
-4% -$258K ﹤0.01% 1859
2020
Q2 		$8.04M Sell
1,686,808
-94,441
-5% -$377K ﹤0.01% 1634
2020
Q1 		$3.56M Buy
1,781,249
+712,751
+67% +$1.96M ﹤0.01% 1894
2019
Q4 		$3.69M Buy
1,068,498
+245,616
+30% +$618K ﹤0.01% 2145
2019
Q3 		$2.36M Buy
822,882
+4,649
+0.6% +$14.5K ﹤0.01% 2330
2019
Q2 		$3.1M Buy
+818,233
New +$4.92M ﹤0.01% 2234

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Nuveen's BCRX Position: Q2 2026 in Review

Nuveen increased its BioCryst Pharmaceuticals (BCRX) stake by 4.9% in Q2 2026, buying an estimated $1.7M and bringing the position to 4,007,237 shares worth $40.1M. The position accounts for 0.01% of the portfolio, ranked #837.

Nuveen first reported a position in BCRX in Q2 2019 and has held it in 29 quarters since. The position peaked at $40.6M in Q2 2021. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Nuveen held 4,007,237 shares of BioCryst Pharmaceuticals worth $40.1M as of Q2 2026.
  • Nuveen bought 187,974 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.7M.
  • BioCryst Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #837 holding.
  • Nuveen first reported a position in BioCryst Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's BioCryst Pharmaceuticals position peaked at $40.6M in Q2 2021.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.